Celldex Therapeutics, Inc.
HealthcareNASDAQ:CLDX · NASDAQ Capital Market
+$1.31 today
Vol 0.60M · Avg 0.94M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.1%
avg -44.6%
ROIC
-53.9%
avg -41.8%
ROA
-44.4%
avg -37.0%
Analysis
ROA is currently the strongest return metric at -44.4% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anthony S. Marucci | Founder, President, Chief Executive Officer & Director | $1.34M | — | 64 | $300,000.00 | 0.45% |
Tibor Keler | Founder, Chief Scientific Officer & Executive Vice President | $867,164.00 | — | 67 | $93,000.00 | 0.14% |
Elizabeth Crowley | Chief Product Development Officer & Senior Vice President | $744,058.00 | — | 54 | $85,000.00 | 0.13% |
Sam Martin | Senior Vice President, Chief Financial Officer, Secretary & Treasurer | $739,663.00 | — | 55 | $58,815.00 | 0.09% |
Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | $719,484.00 | — | 69 | $82,000.00 | 0.12% |
Diane C. Young | Senior Vice President & Chief Medical Officer | $696,453.00 | — | 69 | $72,000.00 | 0.11% |
Freddy A. Jimenez | Senior Vice President & General Counsel | $579,698.00 | — | 57 | $30,796.00 | 0.05% |
Teri L. Lawver | Chief Commercial Officer & Senior Vice President | $446,448.00 | — | 59 | $100,000.00 | 0.15% |
Ronald A. Pepin | Chief Business Officer & Senior Vice President | $441,839.00 | — | 70 | $20,097.00 | 0.03% |
Joseph Schlessinger | Co-Founder & Member of Scientific Advisory Board | — | — | 81 | — | — |
Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | — | — | 51 | $78,000.00 | 0.12% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$1.32M
Net Sentiment
$1.32M
Net selling
Most Active
Jimenez Freddy A.
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 4 sells worth $1.32M over the last 12 months. That adds up to net selling of $1.32M. Jimenez Freddy A. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | -21.2% | +41.1% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -21.2% over three years. Forward estimates point to Revenue at +41.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages CLDX?
Celldex Therapeutics, Inc. (CLDX) lists 11 active executives. The top listed executive is Elizabeth Crowley, Chief Product Development Officer & Senior Vice President.
Are CLDX insiders buying or selling?
Recent insider activity shows net buying of $92.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.